Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome

H-P Hartung; M S Freedman; C H Polman; G Edan; L Kappos; D H Miller; X Montalbán; F Barkhof; J Petkau; R White; V Sahajpal; V Knappertz; K Beckmann; V Lanius; R Sandbrink; C Pohl; BENEFIT Study Group; Jette Lautrup Battistini Frederiksen

doi:10.1212/WNL.0b013e31822c90d7

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome

H-P Hartung, M S Freedman, C H Polman, G Edan, L Kappos, D H Miller, X Montalbán, F Barkhof, J Petkau, R White, V Sahajpal, V Knappertz, K Beckmann, V Lanius, R Sandbrink, C Pohl, BENEFIT Study Group, Jette Lautrup Battistini Frederiksen

Afdeling for Hjerne- og Nervesygdomme NEU

42 Citationer (Scopus)

Abstract

To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon β-1b (IFNβ-1b).

Originalsprog	Engelsk
Tidsskrift	Neurology
Vol/bind	77
Udgave nummer	9
Sider (fra-til)	835-43
Antal sider	9
ISSN	0028-3878
DOI	https://doi.org/10.1212/WNL.0b013e31822c90d7
Status	Udgivet - 2011

Adgang til dokumentet

10.1212/WNL.0b013e31822c90d7

Andre filer og links

Link to publication in Scopus

Citationsformater

Hartung, H.-P., Freedman, M. S., Polman, C. H., Edan, G., Kappos, L., Miller, D. H., Montalbán, X., Barkhof, F., Petkau, J., White, R., Sahajpal, V., Knappertz, V., Beckmann, K., Lanius, V., Sandbrink, R., Pohl, C., BENEFIT Study Group, & Frederiksen, J. L. B. (2011). Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology, 77(9), 835-43. https://doi.org/10.1212/WNL.0b013e31822c90d7

Hartung, H-P, Freedman, MS, Polman, CH, Edan, G, Kappos, L, Miller, DH, Montalbán, X, Barkhof, F, Petkau, J, White, R, Sahajpal, V, Knappertz, V, Beckmann, K, Lanius, V, Sandbrink, R, Pohl, C, BENEFIT Study Group & Frederiksen, JLB 2011, 'Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome', Neurology, bind 77, nr. 9, s. 835-43. https://doi.org/10.1212/WNL.0b013e31822c90d7

@article{0f457225ff734bb5ae389f8803dfba12,

title = "Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome",

abstract = "To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon β-1b (IFNβ-1b).",

keywords = "Antibodies, Neutralizing, Cross-Sectional Studies, Demyelinating Diseases, Follow-Up Studies, Humans, Injections, Subcutaneous, Interferon-beta, Longitudinal Studies, Multiple Sclerosis, Prospective Studies",

author = "H-P Hartung and Freedman, \{M S\} and Polman, \{C H\} and G Edan and L Kappos and Miller, \{D H\} and X Montalb{\'a}n and F Barkhof and J Petkau and R White and V Sahajpal and V Knappertz and K Beckmann and V Lanius and R Sandbrink and C Pohl and \{BENEFIT Study Group\} and Frederiksen, \{Jette Lautrup Battistini\}",

year = "2011",

doi = "10.1212/WNL.0b013e31822c90d7",

language = "English",

volume = "77",

pages = "835--43",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome

AU - Hartung, H-P

AU - Freedman, M S

AU - Polman, C H

AU - Edan, G

AU - Kappos, L

AU - Miller, D H

AU - Montalbán, X

AU - Barkhof, F

AU - Petkau, J

AU - White, R

AU - Sahajpal, V

AU - Knappertz, V

AU - Beckmann, K

AU - Lanius, V

AU - Sandbrink, R

AU - Pohl, C

AU - BENEFIT Study Group

AU - Frederiksen, Jette Lautrup Battistini

PY - 2011

Y1 - 2011

N2 - To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon β-1b (IFNβ-1b).

AB - To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon β-1b (IFNβ-1b).

KW - Antibodies, Neutralizing

KW - Cross-Sectional Studies

KW - Demyelinating Diseases

KW - Follow-Up Studies

KW - Humans

KW - Injections, Subcutaneous

KW - Interferon-beta

KW - Longitudinal Studies

KW - Multiple Sclerosis

KW - Prospective Studies

UR - https://www.scopus.com/pages/publications/80055068683

U2 - 10.1212/WNL.0b013e31822c90d7

DO - 10.1212/WNL.0b013e31822c90d7

M3 - Journal article

C2 - 21849647

SN - 0028-3878

VL - 77

SP - 835

EP - 843

JO - Neurology

JF - Neurology

IS - 9

ER -

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater